Medtronic plc (MDT), Friday announced that its Altaviva device, designed to treat urge urinary incontinence, has secured U.S. Food and Drug Administration approval.
Designed for real-life needs, the Altaviva device is MRI-compatible, providing patients with peace of mind for planned or unexpected medical imaging, the company stated.
The device is inserted near the ankle during a minimally invasive procedure. It sits slightly below the skin and sends electrical impulses to the tibial nerve, helping restore communication between the bladder and the brain to regulate bladder control.
In the pre-market hours, MDT is trading at $96.05, up 0.49 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.